Literature DB >> 7785997

Fluconazole, D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice.

J R Graybill1, L K Najvar, J D Holmberg, M F Luther.   

Abstract

D0870 is a recently developed triazole with characteristics of a broad spectrum of activity and slow clearance by nonrenal mechanisms. Herein we have evaluated the efficacy of D0870, alone and combined with flucytosine, in a murine model of disseminated Candida tropicalis infection. Four isolates of C. tropicalis were evaluated. Two were highly susceptible in vitro to fluconazole, and two were resistant to fluconazole. All were highly susceptible to flucytosine and D0870. Animals were pretreated with 5-fluorouracil 1 day before infection because C. tropicalis has reduced virulence in immunocompetent mice. This was done to render them neutropenic for > 10 days. Mice were infected intravenously and treated orally with D0870 or fluconazole, alone or combined with flucytosine. Survival and tissue burden of the spleen and kidneys were used to evaluate the efficacy of antifungal therapy. Fluconazole was less effective for treatment of resistant C. tropicalis than susceptible C. tropicalis. D0870 was more potent than fluconazole and was effective in fluconazole-resistant isolates. Flucytosine was consistently effective when used alone but did not consistently add to the benefit of D0870 or fluconazole. D0870 has potential in treatment of candidiasis caused by C. tropicalis, including fluconazole-resistant isolates.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7785997      PMCID: PMC162655          DOI: 10.1128/AAC.39.4.924

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Authors:  M J Humphrey; S Jevons; M H Tarbit
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

2.  Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis.

Authors:  R Allendoerfer; A J Marquis; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 3.  Current strategies for treating invasive candidiasis: emphasis on infections in nonneutropenic patients.

Authors:  J E Edwards; S G Filler
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

4.  Candida tropicalis: a major pathogen in immunocompromised patients.

Authors:  J R Wingard; W G Merz; R Saral
Journal:  Ann Intern Med       Date:  1979-10       Impact factor: 25.391

  4 in total
  12 in total

1.  Combined therapies in a murine model of blastoschizomycosis.

Authors:  Carolina Serena; M Mar Rodríguez; Marçal Mariné; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

2.  Pharmacokinetics of two multiple-dosing regimens of D0870 in human immunodeficiency virus-positive patients: a phase I study.

Authors:  S De Wit; E O'Doherty; J Edwards; R Yates; R P Smith; A N Clumeck
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 3.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

4.  Efficacy of D0870 treatment of experimental Candida vaginitis.

Authors:  P L Fidel; J L Cutright; J D Sobel
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

5.  In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.

Authors:  M A Pfaller; S A Messer; L Boyken; H Huynh; R J Hollis; D J Diekema
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

6.  Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750.

Authors:  F Barchiesi; D Calabrese; D Sanglard; L Falconi Di Francesco; F Caselli; D Giannini; A Giacometti; S Gavaudan; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

7.  In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.

Authors:  D Andes; M van Ogtrop
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 8.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

9.  Synergistic effects of amiodarone and fluconazole on Candida tropicalis resistant to fluconazole.

Authors:  Cecília Rocha da Silva; João Batista de Andrade Neto; José Júlio Costa Sidrim; Maria Rozzelê Ferreira Angelo; Hemerson Iury Ferreira Magalhães; Bruno Coêlho Cavalcanti; Raimunda Sâmia Nogueira Brilhante; Danielle Silveira Macedo; Manoel Odorico de Moraes; Marina Duarte Pinto Lobo; Thalles Barbosa Grangeiro; Hélio Vitoriano Nobre Júnior
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

Review 10.  Treatment of invasive candidiasis in immunocompromised pediatric patients.

Authors:  Brian T Fisher; Theoklis E Zaoutis
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.